Trial Profile

EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 16 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Aug 2023 Phase of the trial is changed from phase 1 to phase 1/2. Number of treatment arms have been increased from 4 to 6 by the addition of experimental cohorts 5 and 6 for the study drug doses of 3000 mg and 4000 mg respectively. Upper age limit of 85 years is removed from inclusion criteria.
10 Aug 2023 Status changed from recruiting to completed.
30 Oct 2019 Results presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2019

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com